Epigallocatechin gallate nanocarriers: from physicochemical design to claim-specific evidence and translational requirements
Year: 2026
Type: article
Abstract: Epigallocatechin gallate (EGCG) is a polyphenolic flavan-3-ol with broad experimental bioactivity, but oral translation is constrained by chemical lability, restricted intestinal transport, active efflux, extensive presystemic metabolism, and highly variable systemic exposure. Nanocarriers can protect EGCG, modify release, enhance local transport, or increase exposure in selected formulations; however, these effects cannot be inferred from particle size, polydispersity index (PDI), zeta potential, or encapsulation efficiency (EE) alone and cannot be generalized across carrier classes. Recent reviews already synthesize EGCG nanocarrier formulations, biological effects, pharmacokinetic observations, safety considerations, and translational challenges. This critical narrative review addresses a complementary question: what formulation-specific evidence is sufficient to support claims of protection, permeability enhancement, pharmacokinetic improvement, efficacy, or human translation? We link intrinsic EGCG chemistry to carrier selection and appraise a defined 31-study formulation-level set by route, dose context, analyte, comparator/control, endpoint, and directly supported magnitude while separating direct from surrogate evidence. An author-developed six-level conceptual hierarchy maps directly measured endpoints from physicochemical characterization to human outcomes, alongside separate appraisal of comparators, controls, analyte specificity, and internal-validity limitations. Its numbering is a heuristic of broad proximity to clinical inference, not a validated study-quality score or a mandatory sequence across routes. Across carrier classes, performance is formulation- and endpoint-specific; translation requires appropriate EGCG-dose-matched comparators, route-appropriate systemic pharmacokinetics or local-delivery evidence, formulation-specific safety, and efficacy rather than favorable particle metrics alone.
Source: Frontiers in Nanotechnology
Authors: Iván D. Mesías-Muñoz(Conceptualization, Investigation, Methodology, Writing – original draft), Paula Jorquera(Investigation, Writing – original draft), Leon Goity(Validation, Writing – review & editing), Gabriela Valenzuela-Barra(Validation, Writing – review & editing), Javier O. Morales(Conceptualization, Funding acquisition, Investigation, Methodology, Supervision, Writing – review & editing)
Language: English
Topic: Tea Polyphenols and Effects
Subfield: Food Science
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,077
Awards: G2277598473, CENTRO AVANZADO DE ENFERMEDADES CRONICAS/ ADVANCED CENTER FOR CHRONIC DISEASES (ACCDIS), A RATIONAL STRATEGY TO ENHANCE THE BUCCAL PERMEATION OF STABLE PEPTIDE-LOADED NANOCARRIERS ELUCIDATING KEY PHYSICOCHEMICAL PROPERTIES OF NANOCARRIERS AND THEIR VEHICLE, CENTRO DE ESTUDIOS AVANZADOS DE ENFERMEDADES CRONICAS (ACCDIS), G8794338893, MULTI-SPECIFIC PEPTIDES FOR HYPERTENSION AND HEART FAILURE POWERED BY TAILORED DRUG DELIVERY SYSTEMS, G9001376385, G99091514
OpenAlex ID: W7234386828
